Verastem (VSTM) Stock Gets a Price Target Boost After Winning FDA Approval

Yesterday, the FDA approved Verastem’s (VSTM) lead product, Copiktra (duvelisib), as the first PI3K-δ/-γ inhibitor for the treatment of third-line chronic lympocytic leukemia (CLL), small …

Oppenheimer Shares Two Cents on Verastem (VSTM) Following Initiation of Phase I/II Duvelisib Study in Combination with Venetoclax

Yesterday, Verastem (VSTM) announced dosing of the first patient in a multicenter Phase I/II clinical trial at the Dana-Farber/Harvard Cancer Center of duvelisib in …

Healthcare Wiz Mitchell Blutt Bets Big on These 3 Biotech Stocks

Hedge fund manager Mitchell J. Blutt of the $1.

Oppenheimer Cuts Price Target on Verastem (VSTM) to Reflect Recent Dilution

Verastem (NASDAQ:VSTM) just riled up Wall Street today with enticing Phase Ib/II study results in chronic lymphocytic leukemia (CLL), sending shares on a …

Here’s Why Verastem Oncology (VSTM) Shares Are Soaring 15% Today

Shares of Verastem Oncology (NASDAQ:VSTM) are up nearly 15% as of 12:04 p.m.

Are These Two Healthcare Stocks Great Bargains? Analysts Say Yes

By Harriet Lefton You don’t need to spend big to pick up premium stock picks… not when you can use the markets’ current …

Verastem (VSTM): Is There More Fuel For The Bulls?

FBR’s George Zavoico believes strong data for Verastem’s lead drug candidate duvelisib helped impress Japan’s Yakult Honsha.

Roth Capital Assigns Buy On Shares Of Verastem, $29 PT

Roth Capital analyst Joseph Pantginis assigned a Buy rating on Verastem (NASDAQ:VSTM) with a $29 price target, which represents a potential upside of 188% …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts